Profile data is unavailable for this security.
About the company
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
- Revenue in USD (TTM)0.00
- Net income in USD-98.79m
- Incorporated2012
- Employees20.00
- LocationRelmada Therapeutics Inc2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES 33134United StatesUSA
- Phone+1 (646) 876-3459
- Websitehttps://www.relmada.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biostem Technologies Inc | -100.00bn | -100.00bn | 134.70m | 67.00 | -- | -- | -- | -- | -- | -- | -- | -0.2692 | -- | -- | -- | -- | -- | -107.46 | -- | -- | -- | 59.17 | -- | -120.14 | 0.4177 | -- | 2.41 | -- | 72.14 | 47.77 | 42.48 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 9.94m | -164.57m | 135.18m | 68.00 | -- | 8.11 | -- | 13.61 | -5.77 | -5.77 | 0.3508 | 0.63 | 0.0482 | -- | 11.73 | 146,102.90 | -79.76 | -54.44 | -95.35 | -64.32 | -- | -- | -1,656.51 | -772.82 | -- | -- | 0.7122 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Repare Therapeutics Inc | 51.13m | -93.80m | 135.40m | 179.00 | -- | 0.6384 | -- | 2.65 | -2.23 | -2.23 | 1.21 | 5.03 | 0.1655 | -- | 5.21 | 285,659.20 | -30.36 | -23.40 | -37.50 | -26.37 | -- | -- | -183.44 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Amylyx Pharmaceuticals Inc | 380.79m | 49.27m | 135.56m | 384.00 | 2.84 | 0.3124 | 2.69 | 0.356 | 0.7045 | 0.7045 | 5.43 | 6.40 | 0.8379 | 1.06 | 13.76 | 991,630.20 | 10.84 | -- | 12.63 | -- | 93.32 | -- | 12.94 | -- | 5.20 | -- | 0.00 | -- | 1,612.94 | -- | 124.84 | -- | -- | -- |
| FitLife Brands Inc | 52.70m | 5.30m | 136.11m | 37.00 | 27.38 | 5.03 | 25.25 | 2.58 | 1.08 | 1.08 | 10.74 | 5.88 | 1.30 | 3.44 | 38.31 | 1,424,297.00 | 13.07 | 26.40 | 15.94 | 33.92 | 40.67 | 42.09 | 10.05 | 17.65 | 0.5419 | 16.81 | 0.4253 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| Zura Bio Ltd | 0.00 | -69.24m | 136.45m | 14.00 | -- | 2.30 | -- | -- | -4.38 | -4.38 | 0.00 | 1.36 | 0.00 | -- | -- | 0.00 | -49.98 | -- | -60.56 | -- | -- | -- | -- | -- | -- | -- | 0.0123 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Elite Pharmaceuticals Inc | 47.32m | 15.55m | 138.21m | 53.00 | 8.90 | 2.98 | 8.17 | 2.92 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
| Inotiv Inc | 585.17m | -33.21m | 139.79m | 1.96k | -- | 0.55 | 6.38 | 0.2389 | -1.29 | -1.29 | 22.73 | 9.85 | 0.6858 | 6.46 | 7.12 | 299,320.70 | -3.96 | -23.84 | -4.62 | -29.26 | 30.29 | 29.31 | -5.78 | -33.24 | 1.28 | 0.1431 | 0.5988 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Omega Therapeutics Inc | 3.10m | -97.43m | 140.92m | 93.00 | -- | 2.43 | -- | 45.53 | -1.81 | -1.81 | 0.0573 | 1.05 | 0.0177 | -- | 0.9172 | 33,279.57 | -55.62 | -- | -64.61 | -- | -- | -- | -3,147.92 | -- | -- | -- | 0.2456 | -- | 49.25 | -- | 5.13 | -- | -- | -- |
| Relmada Therapeutics Inc | 0.00 | -98.79m | 141.22m | 20.00 | -- | 1.65 | -- | -- | -3.28 | -3.28 | 0.00 | 2.84 | 0.00 | -- | -- | 0.00 | -78.89 | -- | -87.51 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| CytoDyn Inc | 0.00 | -51.69m | 143.96m | 12.00 | -- | -- | -- | -- | -0.055 | -0.055 | 0.00 | -0.1206 | 0.00 | -- | -- | 0.00 | -414.98 | -259.98 | -- | -- | -- | -- | -- | -235,303.80 | -- | -0.88 | -- | -- | -100.00 | -- | 62.14 | -- | -- | -- |
| I-Mab ADR | 3.82m | -202.49m | 146.07m | 318.00 | -- | 0.6154 | -- | 38.25 | -2.28 | -2.28 | 0.0445 | 2.94 | 0.0083 | -- | -- | -- | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -- | -- |
| GlycoMimetics Inc | 10.00k | -36.90m | 146.95m | 35.00 | -- | 3.82 | -- | 14,694.69 | -0.5841 | -0.5841 | 0.0002 | 0.5966 | 0.0002 | -- | 0.0625 | 285.71 | -75.98 | -43.60 | -90.65 | -47.82 | -- | -- | -368,994.20 | -2,243.52 | -- | -- | 0.00 | -- | -86.67 | -- | 20.97 | -- | -29.82 | -- |
| ASP Isotopes Inc | 433.03k | -16.29m | 148.73m | 76.00 | -- | 9.13 | -- | 343.46 | -0.5016 | -0.5016 | 0.0131 | 0.3331 | 0.0216 | -- | -- | 5,697.76 | -81.39 | -- | -109.02 | -- | 32.09 | -- | -3,762.82 | -- | -- | -251.76 | 0.0378 | -- | -- | -- | -229.34 | -- | -- | -- |
| Vaxart Inc | 7.38m | -82.47m | 150.58m | 109.00 | -- | 2.30 | -- | 20.41 | -0.5844 | -0.5844 | 0.0519 | 0.3767 | 0.0601 | -- | 4.87 | 67,697.25 | -67.13 | -49.60 | -77.06 | -54.86 | -- | -- | -1,117.56 | -1,398.00 | -- | -- | 0.10 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
Data as of Apr 18 2024. Currency figures normalised to Relmada Therapeutics Inc's reporting currency: US Dollar USD
28.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Deep Track Capital LPas of 31 Dec 2023 | 2.04m | 6.78% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.30m | 4.31% |
| Acadian Asset Management LLCas of 31 Dec 2023 | 1.18m | 3.92% |
| Parsons Capital Management, Inc.as of 31 Dec 2023 | 949.84k | 3.15% |
| Opaleye Management, Inc.as of 31 Dec 2023 | 877.00k | 2.91% |
| Palo Alto Investors LPas of 31 Dec 2023 | 732.40k | 2.43% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 565.60k | 1.87% |
| Two Sigma Advisers LPas of 31 Dec 2023 | 328.30k | 1.09% |
| Two Sigma Investments LPas of 31 Dec 2023 | 302.74k | 1.00% |
| Horizons ETFs Management (Canada), Inc.as of 31 Dec 2023 | 270.40k | 0.90% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
